Antibiotics create a shift from mutualism to competition in human gut communities with a longer-lasting impact on fungi than bacteria.
Journal
Microbiome
ISSN: 2049-2618
Titre abrégé: Microbiome
Pays: England
ID NLM: 101615147
Informations de publication
Date de publication:
12 09 2020
12 09 2020
Historique:
received:
15
05
2020
accepted:
24
07
2020
entrez:
13
9
2020
pubmed:
14
9
2020
medline:
31
3
2021
Statut:
epublish
Résumé
Antibiotic treatment has a well-established detrimental effect on the gut bacterial composition, but effects on the fungal community are less clear. Bacteria in the lumen of the gastrointestinal tract may limit fungal colonization and invasion. Antibiotic drugs targeting bacteria are therefore seen as an important risk factor for fungal infections and induced allergies. However, antibiotic effects on gut bacterial-fungal interactions, including disruption and resilience of fungal community compositions, were not investigated in humans. We analysed stool samples collected from 14 healthy human participants over 3 months following a 6-day antibiotic administration. We integrated data from shotgun metagenomics, metatranscriptomics, metabolomics, and fungal ITS2 sequencing. While the bacterial community recovered mostly over 3 months post treatment, the fungal community was shifted from mutualism at baseline to competition. Half of the bacterial-fungal interactions present before drug intervention had disappeared 3 months later. During treatment, fungal abundances were associated with the expression of bacterial genes with functions for cell growth and repair. By extending the metagenomic species approach, we revealed bacterial strains inhibiting the opportunistic fungal pathogen Candida albicans. We demonstrated in vitro how C. albicans pathogenicity and host cell damage might be controlled naturally in the human gut by bacterial metabolites such as propionate or 5-dodecenoate. We demonstrated that antibacterial drugs have long-term influence on the human gut mycobiome. While bacterial communities recovered mostly 30-days post antibacterial treatment, the fungal community was shifted from mutualism towards competition. Video abstract.
Sections du résumé
BACKGROUND
Antibiotic treatment has a well-established detrimental effect on the gut bacterial composition, but effects on the fungal community are less clear. Bacteria in the lumen of the gastrointestinal tract may limit fungal colonization and invasion. Antibiotic drugs targeting bacteria are therefore seen as an important risk factor for fungal infections and induced allergies. However, antibiotic effects on gut bacterial-fungal interactions, including disruption and resilience of fungal community compositions, were not investigated in humans. We analysed stool samples collected from 14 healthy human participants over 3 months following a 6-day antibiotic administration. We integrated data from shotgun metagenomics, metatranscriptomics, metabolomics, and fungal ITS2 sequencing.
RESULTS
While the bacterial community recovered mostly over 3 months post treatment, the fungal community was shifted from mutualism at baseline to competition. Half of the bacterial-fungal interactions present before drug intervention had disappeared 3 months later. During treatment, fungal abundances were associated with the expression of bacterial genes with functions for cell growth and repair. By extending the metagenomic species approach, we revealed bacterial strains inhibiting the opportunistic fungal pathogen Candida albicans. We demonstrated in vitro how C. albicans pathogenicity and host cell damage might be controlled naturally in the human gut by bacterial metabolites such as propionate or 5-dodecenoate.
CONCLUSIONS
We demonstrated that antibacterial drugs have long-term influence on the human gut mycobiome. While bacterial communities recovered mostly 30-days post antibacterial treatment, the fungal community was shifted from mutualism towards competition. Video abstract.
Identifiants
pubmed: 32919472
doi: 10.1186/s40168-020-00899-6
pii: 10.1186/s40168-020-00899-6
pmc: PMC7488854
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Video-Audio Media
Langues
eng
Sous-ensembles de citation
IM
Pagination
133Références
Infect Immun. 2004 Sep;72(9):4996-5003
pubmed: 15321991
Science. 2012 Jun 8;336(6086):1314-7
pubmed: 22674328
Nucleic Acids Res. 2016 Jan 4;44(D1):D604-9
pubmed: 26578596
Nat Rev Microbiol. 2010 May;8(5):340-9
pubmed: 20348933
Genome Med. 2016 Jun 15;8(1):67
pubmed: 27306058
ISME J. 2017 Mar;11(3):676-690
pubmed: 27858930
J Med Microbiol. 2011 Nov;60(Pt 11):1643-1650
pubmed: 21778264
Nature. 2019 Oct;574(7777):264-267
pubmed: 31578522
ISME J. 2020 Jul;14(7):1809-1820
pubmed: 32313261
Nat Microbiol. 2018 Mar;3(3):356-366
pubmed: 29335555
Nat Methods. 2012 Jun 10;9(8):811-4
pubmed: 22688413
Nat Microbiol. 2018 Nov;3(11):1255-1265
pubmed: 30349083
BMC Genomics. 2016 Oct 21;17(1):819
pubmed: 27769168
Nature. 2012 Jun 13;486(7402):207-14
pubmed: 22699609
Cell Rep. 2018 Jul 31;24(5):1190-1202.e5
pubmed: 30067975
Ultramicroscopy. 2004 Aug;100(3-4):153-61
pubmed: 15231305
Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4554-61
pubmed: 20847294
Appl Environ Microbiol. 2009 Dec;75(23):7537-41
pubmed: 19801464
Nucleic Acids Res. 2012 Jan;40(Database issue):D615-20
pubmed: 22102573
Front Pharmacol. 2015 May 15;6:98
pubmed: 26029106
Microbiome. 2017 Aug 1;5(1):87
pubmed: 28760163
Cell Host Microbe. 2019 Mar 13;25(3):432-443.e6
pubmed: 30870623
Nat Protoc. 2018 Dec;13(12):2781-2800
pubmed: 30382244
Sci Rep. 2019 Jun 20;9(1):8872
pubmed: 31222159
PLoS One. 2017 Jul 28;12(7):e0182392
pubmed: 28753663
Nature. 2010 Mar 4;464(7285):59-65
pubmed: 20203603
PLoS Comput Biol. 2017 Nov 15;13(11):e1005852
pubmed: 29140991
PLoS One. 2011 Mar 08;6(3):e17447
pubmed: 21408168
Nat Biotechnol. 2015 Oct;33(10):1045-52
pubmed: 26344404
Nat Microbiol. 2018 Mar;3(3):337-346
pubmed: 29311644
Biomed Environ Sci. 2018 Nov;31(11):816-828
pubmed: 30558702
Nat Microbiol. 2016 Jun 27;1(9):16093
pubmed: 27562254
Methods Ecol Evol. 2015 Aug;6(8):973-980
pubmed: 27570615
Infect Immun. 2012 Jan;80(1):150-8
pubmed: 21986629
Nat Commun. 2018 Sep 10;9(1):3663
pubmed: 30202057
Pathog Dis. 2018 Apr 1;76(3):
pubmed: 29648597
Gut Microbes. 2016 May 3;7(3):189-200
pubmed: 26963409
Cell Host Microbe. 2018 Dec 12;24(6):847-856.e4
pubmed: 30503509
Cell Host Microbe. 2016 Jun 8;19(6):865-73
pubmed: 27237365
Future Microbiol. 2017 Feb;12:157-170
pubmed: 28139139
Curr Opin Gastroenterol. 2015 Jan;31(1):69-75
pubmed: 25394236
Nat Methods. 2013 Dec;10(12):1200-2
pubmed: 24076764
Microbiol Mol Biol Rev. 2011 Dec;75(4):583-609
pubmed: 22126995
Cell Host Microbe. 2014 Jan 15;15(1):95-102
pubmed: 24439901
ISME J. 2013 Feb;7(2):269-80
pubmed: 23038174
Microb Cell. 2018 Mar 07;5(5):249-255
pubmed: 29796389
Nat Rev Microbiol. 2014 Oct;12(10):661-72
pubmed: 25198138
Nat Commun. 2018 Nov 23;9(1):4956
pubmed: 30470746
Bioinformatics. 2012 Aug 15;28(16):2106-13
pubmed: 22711789
PLoS One. 2013 Aug 19;8(8):e71806
pubmed: 23977147
Nat Commun. 2017 Dec 22;8(1):2260
pubmed: 29273717
Genome Res. 2017 Apr;27(4):626-638
pubmed: 28167665
Gut. 2014 Aug;63(8):1275-83
pubmed: 24021287
Nat Methods. 2018 Nov;15(11):962-968
pubmed: 30377376
Cell Host Microbe. 2018 Dec 12;24(6):755-757
pubmed: 30543774
Nature. 2017 Nov 23;551(7681):507-511
pubmed: 29143816
J Chromatogr A. 2017 Jun 23;1503:57-64
pubmed: 28499599
Microbiome. 2018 Sep 1;6(1):152
pubmed: 30172257
Nat Biotechnol. 2014 Aug;32(8):822-8
pubmed: 24997787
ISME J. 2016 Mar;10(3):707-20
pubmed: 26359913
J Antimicrob Chemother. 2011 Nov;66(11):2573-80
pubmed: 21911344
Appl Microbiol Biotechnol. 2011 Oct;92(2):381-92
pubmed: 21881891
Nat Rev Microbiol. 2018 Jul;16(7):410-422
pubmed: 29795328